arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Jazz Pharmaceuticals plc

JAZZ
$256.32 ▼ -0.59 (-0.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Jazz Pharmaceuticals plc faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $15.9B
Dividend Yield
Revenue Growth 19.1%
Op. Margin 31.5%
ROIC 2.7%
FCF / Share $6.28
Trailing P/E 54.2x
Price / Book 3.5x
FCF Yield 2.5%
Debt / Equity 1.18
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.07B
↑ +19.1%
Net Income Profit after all expenses
$293.10M
↑ +44.1%
Operating Margin Operating profit as % of sales
31.5%
↑ +48.2% 15th
FCF / Share Free cash flow per share
$6.28
↓ -8.0%
Long-Term Debt Long-term obligations
$5.35B
— -0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
42
Returns
35
Financial Health
33
Cash Quality
4

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters